NGGT Biotechnology’s Gene Therapy NGGT001 Improves Vision in Patients With Bietti’s Crystalline Dystrophy
Next Generation Gene Therapeutics (NGGT) Biotechnology’s NGGT001, an investigational adeno-associated virus (AAV) vector-based gene therapy intended to treat Bietti’s crystalline corneoretinal dystrophy (BCD), improved the vision of patients treated in 2- …